Global $71.3 Bn Gastrointestinal Drugs Market to 2027: Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
DUBLIN, Dec. 7, 2020 /PRNewswire/ -- The "Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
The market is expected to reach US$ 71,300.28 million in 2027 from US$ 49,043.38 million in 2019. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
Based on drug class, the market is segmented in to acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others.
In 2019, the acid neutralizers segment held the largest share of the market. The biologics segment is expected to grow at the fastest CAGR during the forecast period. The advent of biologics has had a significant impact on the management of inflammatory bowel disease (IBD). Treatment with biologics has led to an improved quality of life for patients living with Crohn's disease and ulcerative colitis, with fewer admissions to the hospital and less side effects from corticosteroids.
These are the most recently developed treatments for IBD. Biologic therapies are indicated for people with moderately to severely active disease who have not responded well to conventional therapy. Four of these agents (adalimumab, certolizumab pegol, golimumab and infliximab) target an inflammatory protein called tumor necrosis factor (TNF). Natalizumab and vedolizumab work by blocking certain types of white blood cells from getting into inflamed tissues.
Biologics are beneficial for patients with gastrointestinal disorders who are not responding to conventional treatment. For instance, infliximab, which is derived from monoclonal antibodies to tumor necrosis factor is another modifier of the immune system's actions. Infliximab is given as a series of infusions by vein. This drug can be given to treat moderate to severe Crohn's disease that has not responded to other drugs, to treat people with fistulas, and to maintain response when the disease is difficult to control.
Vedolizumab and natalizumab are drugs for people who have moderate to severe Crohn's diseasethat have not responded to TNF inhibitors or other immunomodulating drugs. With the increasing number of biologics in pipeline, the segment is expected to grow at a rapid pace during the forecast period. For instance, Takeda Pharmaceutical Company Limited has five candidates in different phases for various GI indications.
Sanofi; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Bausch Health; AstraZeneca; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Bayer AG; Celltrion Healthcare Co. , Ltd; and LEXICON PHARMACEUTICALS, INC. are among the leading companies operating in the gastrointestinal drugs market.
Key Topics Covered:
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
2. Gastrointestinal Drugs Market - Key Takeaways
3. Research Methodology
4. Global Gastrointestinal Drugs- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Gastrointestinal Drugs Market- Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Increase in Development of Biologics
5.2 Market Restraints
5.2.1 Low Awareness Associated with Gastrointestinal Disorders in Low-Income Economies
5.3 Market Opportunities
5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
5.4 Future Trends
5.4.1 Emergence of Biosimilars
5.5 Impact Analysis
6. Gastrointestinal Drugs Market - Global Analysis
6.1 Global Gastrointestinal Drugs Marker Revenue Forecast And Analysis
6.2 Global Gastrointestinal Drugs Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Gastrointestinal Drugs Market Analysis - By Drug Class
7.1 Overview
7.2 Gastrointestinal Drugs Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 Acid Neutralizers: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Antidiarrheal and Laxatives
7.5 Anti-Inflammatory Drugs
7.6 Antiemetic and Antinauseants
7.7 Biologics
8. Gastrointestinal Drugs Market Analysis - By Route of Administration
8.1 Overview
8.2 Gastrointestinal Drugs Market Share, by Route of Administration, 2019 and 2027
8.3 Oral
8.3.1 Overview
8.3.2 Oral: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Parenteral
9. Gastrointestinal Drugs Market Analysis - By Application
9.1 Overview
9.2 Gastrointestinal Drugs Market Revenue Share, by Application (2019 and 2027)
9.3 Inflammatory Ulcerative Colitis
9.3.1 Overview
9.3.2 Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Crohn's Disease
9.5 Irritable Bowel Syndrome
9.6 Gastroenteritis
9.7 Celiac Disease
10. Gastrointestinal Drugs Market Analysis - By Distribution Channel
10.1 Overview
10.2 Gastrointestinal Drugs Market Share, by Distribution Channel, 2019 and 2027
10.3 Hospital Pharmacies
10.3.1 Overview
10.3.2 Hospital Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)
10.4 Retail Pharmacies
10.5 Online Pharmacies
11. Gastrointestinal Drugs Market Analysis And Forecast To 2027 - Geographical Analysis
12. Impact of COVID-19 Pandemic on Global Gastrointestinal Drugs Market
13. Gastrointestinal Drugs Market-Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.4 Inorganic Developments
14. Company Profiles
14.1 Key Facts
14.2 Business Description
14.3 Products and Services
14.4 Financial Overview
14.5 SWOT Analysis
14.6 Key Developments
- Sanofi
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- Bausch Health
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Bayer AG
- Celltrion Healthcare Co.,Ltd
- Lexicon Pharmaceuticals, Inc
For more information about this report visit https://www.researchandmarkets.com/r/9aargr
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article